Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the c ...

Quantifying blood flow instead of relying on angiography alone led to a change in diagnosis for 53% of patients.

Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Q3, 2025 Earnings Conference Call. An audio recording of this webcast will be available shortly after the call today on ...

Q3 2025 Earnings Call Transcript November 12, 2025 GLOBALFOUNDRIES Inc. beats earnings expectations. Reported EPS is $0.41, ...

Q3 2025 Earnings Call November 12, 2025 5:00 PM ESTCompany ParticipantsLily Arteaga - Head of Investor RelationsMichael Tiedemann ...

Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 - - Reported highly positive 12-week primary endpoint results from Phase 2 ...